Kiniksa Pharmaceuticals Stock Price History
KNSA Stock | USD 22.08 0.24 1.08% |
Below is the normalized historical share price chart for Kiniksa Pharmaceuticals extending back to May 24, 2018. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Kiniksa Pharmaceuticals stands at 22.08, as last reported on the 1st of December, with the highest price reaching 22.38 and the lowest price hitting 21.72 during the day.
If you're considering investing in Kiniksa Stock, it is important to understand the factors that can impact its price. Kiniksa Pharmaceuticals has Sharpe Ratio of -0.0731, which conveys that the firm had a -0.0731% return per unit of risk over the last 3 months. Kiniksa Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kiniksa Pharmaceuticals' Risk Adjusted Performance of (0.05), standard deviation of 2.88, and Mean Deviation of 1.94 to check out the risk estimate we provide.
At present, Kiniksa Pharmaceuticals' Total Stockholder Equity is projected to decrease significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 552.6 M, whereas Common Stock Total Equity is forecasted to decline to about 13.4 K. . At present, Kiniksa Pharmaceuticals' Price Earnings Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Book Value Ratio is expected to grow to 2.94, whereas Price To Sales Ratio is forecasted to decline to 4.32. Kiniksa Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 24th of May 2018 | 200 Day MA 21.8746 | 50 Day MA 24.0167 | Beta 0.348 |
Kiniksa |
Sharpe Ratio = -0.0731
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns | KNSA |
Estimated Market Risk
2.9 actual daily | 25 75% of assets are more volatile |
Expected Return
-0.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
-0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Kiniksa Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Kiniksa Pharmaceuticals by adding Kiniksa Pharmaceuticals to a well-diversified portfolio.
Price Book 3.648 | Enterprise Value Ebitda (44.93) | Price Sales 4.1956 | Shares Float 15.3 M | Wall Street Target Price 36 |
Kiniksa Pharmaceuticals Stock Price History Chart
There are several ways to analyze Kiniksa Stock price data. The simplest method is using a basic Kiniksa candlestick price chart, which shows Kiniksa Pharmaceuticals price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
Highest Price | October 28, 2024 | 27.59 |
Lowest Price | November 19, 2024 | 20.82 |
Kiniksa Pharmaceuticals December 1, 2024 Stock Price Synopsis
Various analyses of Kiniksa Pharmaceuticals' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Kiniksa Stock. It can be used to describe the percentage change in the price of Kiniksa Pharmaceuticals from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Kiniksa Stock.Kiniksa Pharmaceuticals Price Daily Balance Of Power | (0.36) | |
Kiniksa Pharmaceuticals Price Action Indicator | (0.09) | |
Kiniksa Pharmaceuticals Price Rate Of Daily Change | 0.99 |
Kiniksa Pharmaceuticals December 1, 2024 Stock Price Analysis
Kiniksa Stock Price History Data
The price series of Kiniksa Pharmaceuticals for the period between Mon, Sep 2, 2024 and Sun, Dec 1, 2024 has a statistical range of 6.77 with a coefficient of variation of 7.72. The daily prices for the period are spread out with arithmetic mean of 24.35. The median price for the last 90 days is 24.49. The company underwent 1:1 stock split on 28th of June 2024.Open | High | Low | Close | Volume | ||
12/01/2024 | 22.34 | 22.38 | 21.72 | 22.08 | ||
11/29/2024 | 22.34 | 22.38 | 21.72 | 22.08 | 126,012 | |
11/27/2024 | 22.10 | 22.48 | 21.94 | 22.32 | 163,971 | |
11/26/2024 | 21.73 | 22.28 | 21.29 | 22.04 | 220,185 | |
11/25/2024 | 21.55 | 22.36 | 21.49 | 21.80 | 358,039 | |
11/22/2024 | 21.16 | 21.48 | 21.12 | 21.28 | 191,939 | |
11/21/2024 | 21.27 | 21.38 | 20.71 | 21.09 | 247,570 | |
11/20/2024 | 20.73 | 21.55 | 20.41 | 21.21 | 245,587 | |
11/19/2024 | 21.38 | 21.50 | 20.62 | 20.82 | 309,398 | |
11/18/2024 | 21.02 | 21.52 | 20.58 | 21.50 | 337,633 | |
11/15/2024 | 21.90 | 21.96 | 21.13 | 21.29 | 259,867 | |
11/14/2024 | 22.46 | 22.57 | 21.71 | 21.81 | 218,427 | |
11/13/2024 | 23.18 | 23.34 | 22.56 | 22.62 | 234,115 | |
11/12/2024 | 22.91 | 23.33 | 22.66 | 22.99 | 427,547 | |
11/11/2024 | 22.86 | 23.52 | 22.86 | 23.04 | 317,327 | |
11/08/2024 | 23.01 | 23.37 | 22.62 | 22.86 | 353,800 | |
11/07/2024 | 23.08 | 23.42 | 22.68 | 23.01 | 314,310 | |
11/06/2024 | 22.90 | 23.17 | 22.17 | 23.03 | 506,008 | |
11/05/2024 | 20.66 | 22.14 | 20.66 | 22.03 | 373,477 | |
11/04/2024 | 22.26 | 22.26 | 21.44 | 21.48 | 446,223 | |
11/01/2024 | 22.83 | 23.37 | 22.26 | 22.48 | 358,298 | |
10/31/2024 | 22.87 | 23.20 | 22.34 | 22.59 | 474,357 | |
10/30/2024 | 23.30 | 23.86 | 23.00 | 23.01 | 357,724 | |
10/29/2024 | 21.32 | 25.36 | 20.26 | 23.27 | 981,842 | |
10/28/2024 | 27.67 | 28.15 | 27.37 | 27.59 | 343,189 | |
10/25/2024 | 27.14 | 27.67 | 26.83 | 27.44 | 204,259 | |
10/24/2024 | 26.85 | 26.98 | 26.33 | 26.92 | 248,785 | |
10/23/2024 | 26.75 | 27.45 | 26.45 | 26.84 | 223,065 | |
10/22/2024 | 25.72 | 27.00 | 25.67 | 26.79 | 219,769 | |
10/21/2024 | 26.08 | 26.33 | 25.68 | 25.89 | 242,723 | |
10/18/2024 | 26.61 | 26.61 | 26.00 | 26.26 | 162,032 | |
10/17/2024 | 26.30 | 26.86 | 26.10 | 26.75 | 222,971 | |
10/16/2024 | 27.20 | 27.35 | 26.30 | 26.32 | 190,656 | |
10/15/2024 | 26.63 | 27.18 | 26.41 | 27.06 | 285,536 | |
10/14/2024 | 26.58 | 26.82 | 26.54 | 26.63 | 322,298 | |
10/11/2024 | 25.55 | 26.69 | 25.52 | 26.56 | 290,542 | |
10/10/2024 | 24.80 | 26.05 | 24.58 | 25.49 | 413,820 | |
10/09/2024 | 24.57 | 25.11 | 24.20 | 24.93 | 325,346 | |
10/08/2024 | 23.93 | 24.63 | 23.64 | 24.47 | 266,110 | |
10/07/2024 | 24.48 | 24.48 | 23.33 | 23.73 | 403,474 | |
10/04/2024 | 24.57 | 24.74 | 24.24 | 24.48 | 142,070 | |
10/03/2024 | 24.37 | 24.87 | 24.06 | 24.29 | 153,553 | |
10/02/2024 | 25.36 | 25.82 | 24.50 | 24.53 | 294,033 | |
10/01/2024 | 24.80 | 25.50 | 24.34 | 25.47 | 353,459 | |
09/30/2024 | 25.13 | 25.35 | 24.70 | 24.99 | 368,700 | |
09/27/2024 | 24.24 | 25.02 | 23.97 | 25.00 | 425,109 | |
09/26/2024 | 24.44 | 24.44 | 23.62 | 23.96 | 276,811 | |
09/25/2024 | 24.46 | 24.73 | 24.05 | 24.10 | 380,903 | |
09/24/2024 | 24.76 | 24.76 | 24.23 | 24.45 | 454,901 | |
09/23/2024 | 25.82 | 25.82 | 24.62 | 24.62 | 427,757 | |
09/20/2024 | 26.23 | 26.25 | 25.45 | 25.64 | 3,247,992 | |
09/19/2024 | 25.85 | 26.78 | 25.66 | 26.25 | 423,999 | |
09/18/2024 | 25.39 | 26.15 | 25.08 | 25.27 | 400,552 | |
09/17/2024 | 25.36 | 25.74 | 24.89 | 25.39 | 295,999 | |
09/16/2024 | 25.38 | 25.41 | 24.61 | 25.16 | 383,583 | |
09/13/2024 | 26.09 | 26.14 | 24.79 | 25.26 | 310,466 | |
09/12/2024 | 24.37 | 24.86 | 24.12 | 24.49 | 271,387 | |
09/11/2024 | 24.25 | 24.89 | 24.01 | 24.34 | 192,191 | |
09/10/2024 | 24.10 | 24.31 | 23.76 | 24.13 | 294,967 | |
09/09/2024 | 24.58 | 24.59 | 23.16 | 24.04 | 668,455 | |
09/06/2024 | 25.39 | 25.82 | 24.52 | 24.93 | 161,896 |
About Kiniksa Pharmaceuticals Stock history
Kiniksa Pharmaceuticals investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Kiniksa is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Kiniksa Pharmaceuticals will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Kiniksa Pharmaceuticals stock prices may prove useful in developing a viable investing in Kiniksa Pharmaceuticals
Last Reported | Projected for Next Year | ||
Common Stock Shares Outstanding | 71.9 M | 57.9 M | |
Net Income Applicable To Common Shares | 210.9 M | 221.4 M |
Kiniksa Pharmaceuticals Quarterly Net Working Capital |
|
Kiniksa Pharmaceuticals Stock Technical Analysis
Kiniksa Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
All Next | Launch Module |
Kiniksa Pharmaceuticals Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Kiniksa Pharmaceuticals' price direction in advance. Along with the technical and fundamental analysis of Kiniksa Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Kiniksa to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
Risk Adjusted Performance | (0.05) | |||
Jensen Alpha | (0.42) | |||
Total Risk Alpha | (0.72) | |||
Treynor Ratio | (0.16) |
Cycle Indicators | ||
Math Operators | ||
Math Transform | ||
Momentum Indicators | ||
Overlap Studies | ||
Pattern Recognition | ||
Price Transform | ||
Statistic Functions | ||
Volatility Indicators | ||
Volume Indicators |
Complementary Tools for Kiniksa Stock analysis
When running Kiniksa Pharmaceuticals' price analysis, check to measure Kiniksa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiniksa Pharmaceuticals is operating at the current time. Most of Kiniksa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiniksa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiniksa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiniksa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance |